NFKB1 and glioblastoma: In this study, we performed a genome‐wide screening in GBM cells treated with and without EGFRvIII and TMZ and identified the PI3K/AKT/NF‐κB pathway responsible for TMZ resistance in EGFRvIII‐expressing GBM cells.